Anticancer drug enhancer
CA 2362426 A1 · Owner: The Kitasato Institute · Inventors: Tsuruo, Takashi; Tomida, Akihiro; Ogiso, Yasunari
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Combined use of a proteasome activity inhibitor with an anticancer agent containing a topoisomerase activity inhibitor makes it possible to inhibit the proteasome activity of promoting the degradation of topoisomerase. Thus the , presence of a sufficient amount of topoisomerase can be ensured in cancer cells and the effect of the anticancer agent containing the topoisomerase activity inhibitor targeted on topoisomerase can be potentiated. Similarly combined use of a proteasome activity inhibitor with DNA strand-injury type anticancer agents (for example, platinum complexes alkylating agents, bleomycins), which directly act on DNA but suffer from regulation or reduction in the effects …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 10, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 10, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 10, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.